Tempus AI (NASDAQ:TEM) EVP Sells $221,325.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 2,951 shares of Tempus AI stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total value of $221,325.00. Following the transaction, the executive vice president owned 135,189 shares in the company, valued at $10,139,175. This represents a 2.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The stock was sold at an average price of $56.00, for a total value of $443,912.00.
• On Tuesday, August 18th, Andrew Polovin sold 22,148 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total transaction of $1,098,762.28.

Tempus AI Stock Down 3.1%

TEM traded down $2.52 on Friday, reaching $77.84. 9,310,212 shares of the company traded hands, compared to its average volume of 7,226,184. The stock’s 50 day moving average price is $57.19 and its 200-day moving average price is $52.90. The company has a market cap of $14.04 billion, a price-to-earnings ratio of -54.06 and a beta of 3.72. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter last year, the firm earned ($0.22) earnings per share. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. On average, sell-side analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Guggenheim upped their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. UBS Group initiated coverage on shares of Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $75.00 target price on shares of Tempus AI in a report on Friday, July 31st. Finally, Rothschild & Co Redburn initiated coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target for the company. Eleven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Tempus AI presently has a consensus rating of “Hold” and an average price target of $69.33.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Eagle Health Investments LP bought a new position in Tempus AI in the 1st quarter worth approximately $11,588,000. Alethea Capital Management LLC bought a new stake in shares of Tempus AI in the fourth quarter valued at approximately $1,863,000. Aristotle Atlantic Partners LLC acquired a new stake in shares of Tempus AI in the first quarter worth $6,179,000. Headlands Technologies LLC bought a new position in Tempus AI during the second quarter worth $2,689,000. Finally, Lingotto Investment Management LLP increased its position in Tempus AI by 45.9% during the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock worth $67,525,000 after acquiring an additional 359,667 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.